OTC Markets EXMKT - Delayed Quote USD

Sangui Biotech International, Inc. (SGBI)

Compare
0.0002
0.0000
(0.00%)
As of April 3 at 4:00:00 PM EDT. Market Open.
Loading Chart for SGBI
  • Previous Close 0.0000
  • Open 0.0015
  • Bid --
  • Ask --
  • Day's Range 0.0015 - 0.0015
  • 52 Week Range 0.0002 - 0.0015
  • Volume 200,000
  • Avg. Volume 377
  • Market Cap (intraday) 41,980
  • Beta (5Y Monthly) 1.64
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0000
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Sangui Biotech International, Inc., through its subsidiaries, engages in the manufacturing and sales of wound treatment and cosmetic products. The company offers artificial oxygen carriers comprising oxygen carrying blood additives and oxygen carrying blood volume substitutes; nano formulations for the regeneration of skin; chitoskin wound pads; Hemospray, a hemoglobin based wound spray; and wound dressing spray under the Granulox brand. Sangui Biotech International, Inc. was incorporated in 1995 and is headquartered in Hamburg, Germany.

www.sanguibiotech.com

--

Full Time Employees

June 30

Fiscal Year Ends

Recent News: SGBI

View More

Performance Overview: SGBI

Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

SGBI
0.00%
S&P 500 (^GSPC)
12.27%

1-Year Return

SGBI
86.67%
S&P 500 (^GSPC)
0.25%

3-Year Return

SGBI
98.95%
S&P 500 (^GSPC)
12.60%

5-Year Return

SGBI
98.02%
S&P 500 (^GSPC)
107.35%

Compare To: SGBI

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: SGBI

View More

Valuation Measures

Annual
As of 4/3/2025
  • Market Cap

    41.98k

  • Enterprise Value

    869.05k

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.52

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    10.75

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    51.91%

  • Return on Assets (ttm)

    54.89%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    269.8k

  • Net Income Avi to Common (ttm)

    140.05k

  • Diluted EPS (ttm)

    -0.0000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    7.71k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    24.99k

Research Analysis: SGBI

View More

Company Insights: SGBI

Research Reports: SGBI

View More

People Also Watch